The DOI matches its Crossref record; 302 of the 302 references it cites were found in a registry or an index.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
Abstract
These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) ( Bandelow et al. 2008a ,b, World J Biol Psychiatry 9:242, see Table 1 ). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–302 of 302
Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia
Caroff, S. N., Davis, V. G., Miller, D. D., Thomas, S., Rosenheck, R. A., McEvoy, J. P., Campbell, E. C., Saltz, B. L., Riggio, S., Chakos, M., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05793yel · Cited by 69
Self-citationPoyurovsky, M., Tal, V., Maayan, R., Gil‐Ad, I., Fuchs, C., & Weizman, A. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.10.004 · Cited by 68
Pharmacological Management of First-Episode Schizophrenia and Related Nonaffective Psychoses
Bradford, D. W., Perkins, D. O., & Lieberman, J. A. (2003) · Drugs · doi:10.2165/00003495-200363210-00001 · Cited by 67
Self-citationYuan, H., Wang, C., Sze, S. C. W., Tong, Y., Tan, Q.-R., Feng, X.-J., Liu, R.-M., Zhang, J.-Z., Zhang, Y., & Zhang, Z. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172473c · Cited by 67
A Multidose Study of Haloperidol Decanoate in the Maintenance Treatment of Schizophrenia
Kane, J. M., Davis, J. M., Schooler, N. R., Marder, S. R., Casey, D. E., Brauzer, B., Mintz, J., & Conley, R. R. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.4.554 · Cited by 67
H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients
Sacchetti, E., Guarneri, L., & Bravi, D. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00872-6 · Cited by 66
Neuroleptic Rechallenge after Neuroleptic Malignant Syndrome: Case Report and Literature Review
Wells, A. J., Sommi, R. W., & Crismon, M. L. (1988) · Annals of Pharmacotherapy · doi:10.1177/106002808802200606 · Cited by 66
Olanzapine pamoate: a stick in time?
Citrome, L. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01900.x · Cited by 65
Baptista, T., Uzcátegui, E., Rangel, N., Fakih, Y. E., Galeazzi, T., Beaulieu, S., & de Baptista, E. A. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2008.01.011 · Cited by 64
A typical Antipsychotic Induced Weight Gain: Pathophysiology and Management
Ananth, J., Venkatesh, R., Burgoyne, K. S., Gadasalli, R., Binford, R., & Gunatilake, S. (2004) · Annals of Clinical Psychiatry · doi:10.1080/10401230490453293 · Cited by 64
Cabergoline Treatment of Risperidone-Induced Hyperprolactinemia
Cavallaro, R., Cocchi, F., Angelone, S. M., Lattuada, E., & Smeraldi, E. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0207 · Cited by 63
Treatment of Weight Gain with Fluoxetine in Olanzapine-Treated Schizophrenic Outpatients
Bustillo, J., Lauriello, J., Parker, K. M., Hammond, R., Rowland, L. M., Bogenschutz, M. P., & Keith, S. J. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300089 · Cited by 62
Tenback, D. E., van Harten, P. N., Slooff, C. J., Belger, M. A., & van Os, J. (2005) · PubMed · Cited by 62
Bai, Y., Chen, T., Wu, B., Hung, C., Lin, W., Hu, T., Lin, C.-Y., & Chou, P. (2006) · Pharmacopsychiatry · doi:10.1055/s-2006-946703 · Cited by 62
Atmaca, M., Kuloğlu, M., Tezcan, E., & Üstündağ, B. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.514 · Cited by 62
A double‐blind, placebo‐controlled trial of sibutramine for clozapine‐associated weight gain
Henderson, D. C., Fan, X., Copeland, P. M., Borba, C. P. C., Daley, T. B., Nguyen, D. D., Zhang, H., Hayden, D. L., Freudenreich, O., Cather, C., et al. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00855.x · Cited by 61
Soares‐Weiser, K., & Rathbone, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000459.pub2 · Cited by 60
Weight decline in patients switching from olanzapine to quetiapine
Gupta, S., Masand, P. S., Virk, S., Schwartz, T. L., Hameed, A., Frank, B. L., & Lockwood, K. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.016 · Cited by 59
Tetrabenazine for the Treatment of Tardive Dyskinesia
Leung, J. G., & Crouse, E. L. B. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p312 · Cited by 59
Clozapine efficacy in tardive dyskinesia in schizophrenic patients
Bassitt, D. P., & Louzã, M. R. (1998) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050039 · Cited by 58
Lu, M., Shen, W. W., & Chen, C.-H. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.09.016 · Cited by 58
Behavioural management of antipsychotic‐induced weight gain: a review
Werneke, U., Taylor, D. M., Sanders, T. A. B., & Wessely, S. C. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.00190.x · Cited by 58
Drug Treatment of Schizophrenia in the 1990s
Fleischhacker, W. W., & Hummer, M. (1997) · Drugs · doi:10.2165/00003495-199753060-00002 · Cited by 57
Maintenance therapy and the natural course of schizophrenia.
Davis, J. M. (1985) · PubMed · Cited by 56
Kinon, B. J., Jeste, D. V., Kollack‐Walker, S., Stauffer, V. L., & Liu‐Seifert, H. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.05.016 · Cited by 56
Management of Weight Gain Associated with Antipsychotics
Birt, J. A. (2003) · Annals of Clinical Psychiatry · doi:10.1023/a:1023280610379 · Cited by 56
Alphs, L. D., Bossie, C. A., Sliwa, J. K., Ma, Y.-W., & Turner, N. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-12 · Cited by 55
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine
Chen, C.-H., Chiu, C.-C., Huang, M., Wu, T., Liu, H.-C., & Lu, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.11.013 · Cited by 54
Neuroleptic Malignant Syndrome
Caroff, S. N., Mann, S. C., Sullivan, K. A., & Campbell, E. C. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-835-5_4 · Cited by 54
Bai, Y., Yu, S.-C., & Lin, C.-C. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1110 · Cited by 54
Benzodiazepines for neuroleptic-induced tardive dyskinesia
Walker, P., & Soares, K. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000205 · Cited by 53
Kim, J. H., Yim, S. J., & Nam, J. H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.10.001 · Cited by 53
(2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890423929 · Cited by 52
Calcium channel blockers for neuroleptic-induced tardive dyskinesia
Essali, A., Deirawan, H., Soares‐Weiser, K., & Adams, C. E. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000206.pub3 · Cited by 50
Long-Acting Injectable Risperidone
Ehret, M. J., & Fuller, M. A. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e085 · Cited by 49
Effects of Antipsychotic Treatment on Tardive Dyskinesia
Tenback, D. E., van Harten, P. N., Slooff, C. J., Belger, M. A., van Os, J., & SOHO Study Group (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0907 · Cited by 49
Behavioral therapy for weight loss in patients with schizophrenia.
Ganguli, R. (2007) · PubMed · Cited by 48
Miodownik, C., Lerner, V., Statsenko, N., Dwolatzky, T., Nemets, B., Berzak, E., & Bergman, J. (2006) · Clinical Neuropharmacology · doi:10.1097/00002826-200603000-00002 · Cited by 47
Cortese, L., Caligiuri, M. P., Williams, R., Schieldrop, P., Manchanda, R., MALLA, A. K., & Harricharan, R. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318160864f · Cited by 47
Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia
Glick, I. D., Correll, C. U., Altamura, A. C., Marder, S. R., Csernansky, J. G., Weiden, P. J., Leucht, S., & Davis, J. M. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r06927 · Cited by 47
Miscellaneous treatments for neuroleptic-induced tardive dyskinesia
Soares‐Weiser, K., Irving, C. B., & Rathbone, J. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000208 · Cited by 47
Nizatidine for the treatment of patients with quetiapine‐induced weight gain
Atmaca, M., Kuloğlu, M., Tezcan, E., Üstündağ, B., & Kilic, N. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.477 · Cited by 47
Stryjer, R., Rosenzcwaig, S., Bar, F., Ulman, A.-M., Weizman, A., & Spivak, B. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181ee7f63 · Cited by 46
Depot haloperidol decanoate for schizophrenia
Quraishi, S. N., David, A. S., Brasil, M. A. A., & Alheira, F. V. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001361 · Cited by 45
Cognitive Behavior Therapy for Weight Gain
Umbricht, D., FLURY, H., & Bridler, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.971 · Cited by 45
Lerner, V., Bergman, J., Statsenko, N., & Miodownik, C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1118 · Cited by 44
Choice of maintenance medication for schizophrenia.
Davis, J. M., & Chen, N. (2003) · PubMed · Cited by 43
Baptista, T., Rangel, N., Fakih, Y. E., Uzcátegui, E., Galeazzi, T., Beaulieu, S., & de Baptista, E. A. (2009) · Pharmacopsychiatry · doi:10.1055/s-0028-1085438 · Cited by 43
Metformin in Obesity Associated With Antipsychotic Drug Administration: A Pilot Study
Baptista, T., Hernandez, L., Prieto, L., Boyero, E. C., & Mendoza, S. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0813b · Cited by 43
Lindenmayer, J., Khan, A., Eerdekens, M., Hove, I. V., & Kushner, S. F. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.08.004 · Cited by 43
Henderson, D. C., Fan, X., Sharma, B., Copeland, P. M., Borba, C. P. C., Boxill, R., Freudenreich, O., Cather, C., Evins, A. E., & GOFF, D. C. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01325.x · Cited by 41
Kutcher, S., Williamson, P., MACKENZIE, S., Marton, P., & Ehrlich, M. (1989) · PubMed · Cited by 40
Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia
Lauriello, J., McEvoy, J. P., Rodriguez, S., Bossie, C. A., & Lasser, R. A. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.006 · Cited by 40
Rosenheck, R. A., Cramer, J. A., Xu, W., Grabowski, J., Douyon, R., Thomas, J. V., Henderson, W., & Charney, D. S. (1998) · Europe PMC (PubMed Central) · Cited by 39
Do effectiveness (“real world”) studies on antipsychotics tell us the real truth?
Möller, H. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0812-0 · Cited by 39
Self-citationBai, Y., Yu, S.-C., & Lin, C.-C. (2003) · PubMed · Cited by 39
Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study
Bai, Y., Yu, S.-C., Chen, J.-Y., Lin, C., Chou, P., & Lin, C.-C. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200503000-00003 · Cited by 39
Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia
Dupuis, B., Catteau, J., Dumon, J. P., Libert, C., & Petit, H. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.6.802 · Cited by 38
Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia
Alabed, S., Latifeh, Y., Mohammad, H. A., & Rifai, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000203.pub3 · Cited by 38
Cookson, I. B. (1987) · International Clinical Psychopharmacology · doi:10.1097/00004850-198704000-00008 · Cited by 38
Kutcher, S., WILLIAMSON, P., MACKENZIE, S., Marton, P., & Ehrlich, M. (1989) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198912000-00003 · Cited by 38
Lee, M., Song, H., An, H., Yang, J.-W., Ko, Y., Jung, I., & Joe, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.02032.x · Cited by 37
Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity
Tchoukhine, E., Takala, P., Hakko, H. H., Raidma, M., Putkonen, H., Räsänen, P. K., Terevnikov, V., Stenberg, J., Eronen, M., & Joffe, G. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05283yel · Cited by 37
Maintenance Treatment of Severe Tardive Dyskinesia With Clozapine
Louzã, M. R., & Bassitt, D. P. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155823.59585.88 · Cited by 37
Orlistat in the Treatment of Psychopharmacologically Induced Weight Gain
Anghelescu, I. G., Klawe, C., & Benkert, O. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00029 · Cited by 36
Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia
Barnes, T. R. E., Soares‐Weiser, K., & Bacaltchuk, J. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001946.pub2 · Cited by 35
Pujalte, D., Bottaï, T., Hüe, B., Alric, R., Pouget, R., Blayac, J., & Petit, P. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199406000-00003 · Cited by 33
Placebo-Controlled Pilot Study of Ramelteon for Adiposity and Lipids in Patients With Schizophrenia
Borba, C. P. C., Fan, X., Copeland, P. M., Paiva, A., Freudenreich, O., & Henderson, D. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822bb573 · Cited by 32
How to grade categories of evidence
Bandelow, B., Zohar, J., Kasper, S. F., & Möller, H. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802456590 · Cited by 32
Self-citationNon-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia
El-Sayeh, H. G. G., da Silva, J. P. L., Rathbone, J., & Soares‐Weiser, K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000458.pub2 · Cited by 32
Sampath, G., Shah, A., Krska, J., & Soni, S. D. (1992) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470070405 · Cited by 29
Ciliberto, N. C., Bossie, C. A., Urioste, R., & Lasser, R. A. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00003 · Cited by 29
Kasper, S. F., Lowry, A. J., Hodge, A. T., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.032 · Cited by 27
Effects of an Educational Intervention on Weight Gain in Patients Treated With Antipsychotics
Mauri, M., Castrogiovanni, S., Simoncini, M., Iovieno, N., Miniati, M., Rossi, A., Dell’Agnello, G., Fagiolini, A. M., Donda, P., & Cassano, G. B. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000237943.57893.e6 · Cited by 27
Crocq, M. A., Набер, Д., LADER, M. H., Thibaut, F., Drici, M., Everitt, B. J., Hall, G. C., Jeunne, C. L., Mittoux, A., Peuskens, J., et al. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.09.001 · Cited by 26
Self-citationNovel Antipsychotics in the Long-term Treatment of Schizophrenia
Möller, H. (2004) · The World Journal of Biological Psychiatry · doi:10.1080/15622970410029902 · Cited by 26
Self-citationEffects of Bromocriptine on Neuroleptic‐Induced Amenorrhea, Galactorrhea and Impotence
Matsuoka, I., Nakai, T., Miyake, M., Hirai, M., & Ikawa, G. (1986) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1986.tb03179.x · Cited by 25
Resnick, S. G., Rosenheck, R. A., Cañive, J. M., Souza, C. D., Stroup, T. S., McEvoy, J. P., Thomas, S., Keefe, R. S. E., Swartz, M. S., & Lieberman, J. A. (2008) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-007-9101-3 · Cited by 25
Self-citationHill, A. L., Sun, B., Karagianis, J. L., Watson, S. B., & McDonnell, D. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-28 · Cited by 24
Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients
Kissling, W., Glue, P., Medori, R., & Simpson, S. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.877 · Cited by 24
Henderson, D. C., Freudenreich, O., Borba, C. P. C., Wang, X., Copeland, P. M., Macklin, E. A., Fan, X., Cather, C., & GOFF, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.009 · Cited by 22
Montgomery, S. A., & van Zwieten-Boot, B. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.05.004 · Cited by 22
Usefulness of Bromocriptine in the Treatment of Amisulpride-induced Hyperprolactinemia
Bliesener, N., Yokusoglu, H., Quednow, B. B., et al. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-827176 · Cited by 22
Diet and gender moderate clozapine‐related weight gain
Heimberg, C., Gallacher, F., Gur, R. C., & Gur, R. E. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100502 · Cited by 21
Modafinil-Associated Weight Loss in a Clozapine-Treated Schizoaffective Disorder Patient
Henderson, D. C., Louie, P. M., Koul, P., Briggs, L. B. N., Daley, T. B., & Nguyen, D. D. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230590932407 · Cited by 21
Sliwa, J. K., Bossie, C. A., Ma, Y.-W., & Alphs, L. D. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.016 · Cited by 21
Reducing Dosage in Maintenance Treatment of Schizophrenia
Schooler, N. R. (1993) · The British Journal of Psychiatry · doi:10.1192/s0007125000292611 · Cited by 21
Ganguli, R., Brar, J. S., Garbut, R., Chang, C.-C. H., & Basu, R. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.2.3 · Cited by 20
Hoffmann, V. P., Case, M. G., & Jacobson, J. G. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05580 · Cited by 19
Kaneda, Y., Kawamura, I., Fujii, A., & Ohmori, T. (2004) · PubMed · Cited by 18
ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia.
van Zwieten-Boot, B. (2007) · Cited by 18
López-Mato, A., Rovner, J., Illa, G., Vieitez, A., & Boullosa, O. (2003) · PubMed · Cited by 18
Altamura, A. C., & Glick, I. D. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709991271 · Cited by 16
Wehmeier, P. M., Kluge, M., Schacht, A., Helsberg, K., Schreiber, W., SCHIMMELMANN, B. G., & Lambert, M. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.07.005 · Cited by 15
Surgery for Tardive Dyskinesia
Thobois, S., Poisson, A., & Damier, P. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00012-2 · Cited by 14
Kilian, R., Steinert, T., Schepp, W., Weiser, P., Jaeger, S., Pfiffner, C., Frasch, K., Eschweiler, G. W., Messer, T., Croissant, D., et al. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0316-9 · Cited by 14
Barinas‐Mitchell, E., Kuller, L. H., Pietropaolo, S. L., Zhang, Y., Henderson, T., & Pietropaolo, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2667 · Cited by 13
Bromperidol decanoate (depot) for schizophrenia
Purgato, M., & Adams, C. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001719.pub4 · Cited by 10
Adjuvant Metformin Worsens Psychosis in Schizophrenia: A Case Report
Venkatasubramanian, G., Arasappa, R., Rao, N. P., Behere, R. V., & Gangadhar, B. N. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.09l00801yel · Cited by 6
Olanzapine-Induced Hyperprolactinemia and Galactorrhea Reversed With Addition of Bromocriptine
Miller, D. E., & Sebastian, C. S. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0217e · Cited by 6
Mendhekar, D. N., Rc, J., Mm, M., et al. (2002) · PubMed · Cited by 5
Farinde, A. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011416672 · Cited by 1
Cited by
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Ringen, P. A., Engh, J. A., Birkenaes, A. B., Dieset, I., & Andreassen, O. A. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00137 · Cited by 339
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292
“The World Federation of Societies of Biological Psychiatry (WFSBP) has published a guideline on the long-term treatment of schizophrenia and management of antipsychotic-induced adverse effects (Hasan et al., 2013), which includes the management of weight gain and metabolic changes.”
Background
Metadata
- Authors
- Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2012-12-06
- Volume
- 14
- Issue
- 1
- Pages
- 2-44
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2107201157
- Cited by
- 416
- References
- 302
- FWCI
- 18.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.